Literature DB >> 35781646

Corrigenda.

.   

Abstract

Entities:  

Year:  2022        PMID： 35781646      PMCID： PMC9394614          DOI： 10.1111/bjd.20960

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN： 0007-0963            Impact factor:   11.113


× No keyword cloud information.
  1 in total

1.  Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks.

Authors:  K Reich; R B Warren; L Iversen; L Puig; I Pau-Charles; A Igarashi; M Ohtsuki; M Falqués; M Harmut; S Rozzo; M G Lebwohl; W Cantrell; A Blauvelt; D Thaçi
Journal:  Br J Dermatol       Date:  2019-07-18       Impact factor: 9.302
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.